Analytical and Clinical Evaluation of the MeltArray Glioma Assay for Rapid Multiplex Detection of 18 Hotspot Mutations in FFPE Gliomas
Year: 2026
Type: article
Abstract: Rapid hotspot mutation testing offers a practical route to integrated glioma diagnosis when tissue availability, turnaround time, or sequencing capacity is limited. We validated the MeltArray Glioma Assay, a laboratory-developed test that detects 18 hotspot mutations across IDH1, IDH2, TERT, histone H3 genes, and BRAF using only two reactions in a four-channel format. Analytical performance was assessed with respect to melting-temperature reproducibility, lowest tested detectable input, mutant allele fraction sensitivity, specificity, and the function of the RPP30 internal control. Assay calls in 168 formalin-fixed, paraffin-embedded gliomas were compared with targeted next-generation sequencing. Melting temperatures were highly reproducible across three independent SLAN-96S instruments of the same model (coefficients of variation, 0.07–0.48%). All 18 mutations were detected at 10 plasmid copies per reaction; at a total input of 1 × 105 plasmid copies per reaction, four mutations were detectable at a 0.1% mutant allele fraction and the remaining mutations at 0.5%. No target-specific melting peaks were observed with 293T cell or healthy-donor genomic DNA. In clinical specimens, the MeltArray assay classified 108 specimens as positive and 60 as negative, showing 100% positive, negative, and overall percentage agreement with sequencing. The 131 mutation events comprised 66 in TERT, 45 in IDH1/2, 10 in histone H3, and 10 in BRAF. The MeltArray assay enables rapid, sensitive hotspot genotyping on a standard four-channel real-time PCR platform and is best positioned as a focused adjunct to comprehensive molecular glioma classification.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7236656547
